Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2019	Agency for Healthcare Research and Quality (AHRQ)	Pharmacologic and nonpharmacologic therapies in adult patients with exacerbation of COPD
2019	National Institute for Health and Care Excellence (NICE)	Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. NICE technology appraisal guidance 607
2019	National Institute for Health and Care Excellence (NICE)	Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers. NICE medical technologies guidance 40
2019	NIHR Health Technology Assessment programme	Peer-led walking programme to increase physical activity in inactive 60- to 70-year-olds: Walk with Me pilot RCT
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bedaquiline (pulmonary multidrug-resistant tuberculosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal). NICE technology appraisal guidance 608
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: HemlibraMC (emicizumab) - Hemophilia A, notice of inclusion on the Liste des produits du système du sang du Québec]
2019	Agency for Care Effectiveness (ACE)	Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Melatonin (sleep disorders) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal). NICE technology appraisal guidance 609
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in July 2019: high blood pressure]
2019	Agency for Care Effectiveness (ACE)	Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Pentosan polysulfate sodium for treating bladder pain syndrome. NICE technology appraisal guidance 610
2019	NIHR Health Technology Assessment programme	Protocolised non-invasive compared with invasive weaning from mechanical ventilation for adults in intensive care: the Breathe RCT
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in October 2019: lipid-lowering pharmacologic agents]
2019	Agency for Care Effectiveness (ACE)	Botulinum toxin A for treating blepharospasm or hemifacial spasm
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 611
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: indications justifying the use of imaging for diagnosing patients with primary or secondary headache]
2019	Agency for Care Effectiveness (ACE)	Oral COX-2 inhibitors for treating pain
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. NICE technology appraisal guidance 612
2019	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with influenza vaccination
2019	Agency for Care Effectiveness (ACE)	Ferric carboxymaltose for treating iron deficiency anaemia
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy. NICE technology appraisal guidance 613
2019	NIHR Health Technology Assessment programme	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT
2019	Adelaide Health Technology Assessment (AHTA)	Faecal calprotectin testing in patients suspected of inflammatory bowel disease (IBD) presenting to primary care
2019	Agency for Care Effectiveness (ACE)	Botulinum toxin A for treating cervical dystonia
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glycerol phenylbutyrate (urea cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Cannabidiol with clobazam for treating seizures associated with Dravet syndrome. NICE technology appraisal guidance 614
2019	NIHR Health Technology Assessment programme	Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT
2019	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for myasthenia gravis
2019	Agency for Care Effectiveness (ACE)	Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Abemaciclib (breast cancer; combination with fulvestrant) - Addendum to Commission A18-73]
2019	National Institute for Health and Care Excellence (NICE)	Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome. NICE technology appraisal guidance 615
2019	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: managing the risk of suicide and self-harm among youths living in rehabilitation centres for young persons with adjustment problems]
2019	Agency for Care Effectiveness (ACE)	Endothelin receptor antagonists for treating pulmonary arterial hypertension
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79]
2019	National Institute for Health and Care Excellence (NICE)	Cladribine for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 616
2019	NIHR Health Services and Delivery Research programme	Exploring the impact of patient experience data in acute NHS hospital trusts in England: using Actor-Network Theory to optimise organisational strategies and practices for improving patients' experiences of care
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mexiletine (myotonia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enzalutamide (prostate cancer) - Addendum to Commission A18-80]
2019	Health Quality Ontario (HQO)	Intermittent Catheters for Chronic Urinary Retention: A Health Technology Assessment
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81]
2019	NIHR Health Technology Assessment programme	Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: withdrawal management in adult addiction rehabilitation service centres]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: the placenta, utility of and indications for the transfer of samples to the anatomical pathology laboratory for analysis]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Determination of the SHI target population for the therapeutic indication type 2 diabetes mellitus using SHI routine data]
2019	NIHR Health Technology Assessment programme	Comprehensive geriatric assessment for frail older people in acute hospitals: the HoW-CGA mixed-methods study.
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: post-tick bite antibiotic prophylaxis to prevent Lyme disease, report in support of the knowledge transfer tools, the Québec’s national medical protocol and the collective prescription template]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Blinatumomab (ALL, paediatric patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	NIHR Health Technology Assessment programme	A workplace-based intervention to increase levels of daily physical activity: the Travel to Work cluster RCT
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: mechanisms for accessing local services]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Blinatumomab (ALL, MRD-positive patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in August 2020: pharmacological treatment of nausea in a person receiving palliative care]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) - Benefit assessment according to §35a Social Code Book V]
2019	Agency for Healthcare Research and Quality (AHRQ)	Telehealth for acute and chronic care consultations
2019	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Gait speed as predictor of frailty]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Organization of care and services for stroke to optimize access to endovascular treatment in Quebec]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Partial breast radiotherapy for patients with early breast cancer after breast conservation surgery
2019	NIHR Health Technology Assessment programme	Development and preliminary evaluation of an intervention package to support parents of excessively crying infants
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (hepatocellular carcinoma) - Addendum to Commission A18-85]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (hepatocellular carcinoma) - Second Addendum to Commission A18-85]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Volume-outcome relationships: pancreaticoduodenectomy (Whipple procedure). Final report
2019	NIHR Health Technology Assessment programme	Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT
2019	NIHR Public Health Research (PHR) programme	A multi-centre individual-randomised controlled trial of screening and brief alcohol intervention to prevent risky drinking in young people aged 14-15 in a high school setting (SIPS JR-HIGH)
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in June 2019: unusual vaginal discharge]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tumour-treating fields in addition to current standard therapy for glioblastoma as first-line treatment - Rapid report]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of low-dose computed tomography lung cancer screening]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (assessment of an orphan drug after exceeding the turnover limit of €1 million)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V]
2019	Agency for Healthcare Research and Quality (AHRQ)	Treatment for acute pain: an evidence map
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: portrait of the Quebec adult trauma care network: 2013 – 2016]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for stem cell transplantation - Rapid report]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Negative pressure wound therapy for wounds healing by primary intention]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brentuximab vedotin (advanced Hodgkin lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	NIHR Public Health Research (PHR) programme	Improving health, under community supervision, with the support of a Health Trainer: developing and evaluating a pilot randomised controlled trial
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	Improving the mental health of children and young people with long term conditions: linked evidence syntheses
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive (AM-RL): Annex XII – Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V brentuximab vedotin (new therapeutic indication: Hodgkin lymphoma, first line)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06]
2019	NIHR Health Technology Assessment programme	Clinical and demographic characteristics associated with delay in help-seeking behaviour in patients with Acute Coronary Syndrome
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: setting safety and conditions for success of vaginal birth after cesarean]
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Intravenous lidocaine for perioperative pain control
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Melatonin (sleep disorders in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) - Addendum to Commission A19-04]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: intensive outpatient services for youths with psychoactive substance use disorders]
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Levalbuterol vs albuterol for hospitalized patients
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endoscopic sleeve gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments
2019	National Institute for Health and Care Excellence (NICE)	Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. NICE diagnostics guidance 37